Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment
We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg...
Main Authors: | M. Benucci, A. Damiani, A. Arena, M. Infantino, M. Manfredi, F. Li Gobbi |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2016-12-01
|
Series: | Reumatismo |
Subjects: | |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/911 |
Similar Items
-
Spondylodiscitis Mimicking Benign Tumors in Ankylosing Spondylitis Patient
by: Fatih Bağcıer, et al.
Published: (2016-08-01) -
Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01) -
CLINICAL EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS
by: O. A. Rumyantseva, et al.
Published: (2018-05-01) -
Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
by: James Cheng-Chung Wei, et al.
Published: (2020-10-01) -
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
by: V. Shobha, et al.
Published: (2019-07-01)